THE USE OF PSYCHOTROPIC MEDICATIONS IN PWS

PWS 中精神药物的使用

• 批准号: 7731411
• 负责人: ELISABETH MAY DYKENS
• 金额: --
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7731411
• 关键词: Age; Behavior; CYP1A2 gene; CYP2C19 gene; CYP2D6 gene; CYP3A4 gene; Caregivers; Clinical; Computer Retrieval of Information on Scientific Projects Database; Dose; Enzymes; Family Caregiver; Feedback; Funding; Gender; Genetic; Genetic Status; Grant; Institution; Journals; Pamphlets; Peer Review; Persons; Pharmaceutical Preparations; Pilot Projects; Population; Prader-Willi Syndrome; Research; Research Personnel; Resources; Source; Symptoms; United States National Institutes of Health; aged; base; cytochrome P450 3A; enzyme activity; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HYPOTHESIS Persons with Prader-Willi syndrome, aged 8 through adulthood, will not differ in their response to various types of psychotropic medications based on their genetic status or polymorphic differences of CYP450 enzyme activity from the population in general. SPECIFIC AIMS In this Pilot Project we specifically propose to: * Identify which regimes of psychotropic medications persons with PWS and their caregivers have found helpful, ineffective or harmful; * Relate treatment responsiveness in persons with PWS to their CYP450 enzyme status (CYP1A2, CYP2C19, CYP2D6, and CYP3A) specifically as rapid, poor, extensive and ultra rapid metabolizers; * Assess the clinical lore that persons with PWS are apt to respond to lower then expected or usual doses of medication due to be poor metabolizers; * Assess additional factors that might be associated with treatment response, including age, gender, genetic subtype of PWS, residential status, and current symptoms and maladaptive behaviors; * Disseminate such findings for both professionals and researchers in the field (e.g., peer-reviewed journals, presentations) and for families and caregivers of offspring with PWS (feedback, booklet, presentations at PWS meetings).

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 假设 prader-willi综合征的患者，年龄8至成年，基于其对CYP450酶活性的遗传状况或多态性差异，其对各种类型的精神药物的反应不会有所不同。 具体目标 在这个试点项目中，我们特别建议： *确定具有PWS及其护理人员的精神药物患者的哪些制度发现有帮助，无效或有害； *将PWS人的治疗反应能力与CYP450酶状态（CYP1A2，CYP2C19，CYP2D6和CYP3A）相关联，特别是快速，贫穷，贫穷，广泛和超快速代谢剂； *评估PWS患者易于应对预期的或常用剂量的药物的临床知识，这是由于代谢不良而响应的； *评估可能与治疗反应相关的其他因素，包括年龄，性别，PW的遗传亚型，住宅状况以及当前症状以及适应不良的行为； *为该领域的专业人士和研究人员（例如，经过同行评审的期刊，演讲）以及带有PWS的后代和护理人员（反馈，小册子，PWS会议上的演讲），分发了此类发现。